Pfizer/Merck KGaA And IPO Hopeful Syndax To Study Ovarian Cancer Combo
This article was originally published in Scrip
Executive Summary
Pfizer Inc. and Merck KGaA, through their 2014 partnership agreement, will evaluate whether the immuno-oncology agent avelumab has the potential to improve treatment options for women with advanced ovarian cancer under a new collaboration with Syndax Pharmaceuticals Inc., a privately-held firm with newly revealed public company aspirations.